CAF

Drug Overview:

CAF refers to the classic three-drug intravenous chemotherapy combination regimen comprising cyclophosphamide, doxorubicin hydrochloride (Adriamycin), and fluorouracil (5-FU), historically established as a foundational systemic therapy for breast cancer management since the 1970s. This multimodal regimen provided significant improvements in disease-free survival for node-positive early-stage breast cancer patients before the advent of modern taxane-containing, dose-dense, and targeted therapy protocols, demonstrating synergistic cytotoxic effects across multiple cell cycle phases while serving as a benchmark for subsequent regimen optimizations in both US and European oncology practices.​

• Generic name: Cyclophosphamide + Doxorubicin hydrochloride + Fluorouracil (combination regimen; no single FDA-approved CAF product)​
• US Brand names: Cytoxan/Neosar (cyclophosphamide), Adriamycin/Rubex (doxorubicin), Adrucil (fluorouracil injection)​
• Drug Class: Alkylating agent (cyclophosphamide) + anthracycline topoisomerase II inhibitor (doxorubicin) + pyrimidine antimetabolite (fluorouracil)​
• Route of Administration: Intravenous (all components administered Day 1 of cycle)​
• FDA Approval Status: Individual components FDA-approved 1959-1970s; CAF regimen established via clinical trials (NSABP B-11/B-15), incorporated in NCCN guidelines as historical standard (now largely replaced by AC→T, TC, dose-dense AC)​

What Is It and How Does It Work? (Mechanism of Action)

CAF orchestrates multimodal DNA damage and nucleotide disruption targeting proliferating tumor cells across G1, S, and M phases, with cyclophosphamide cross-linking DNA, doxorubicin generating lethal strand breaks via topoisomerase poisoning and ROS, and fluorouracil inducing thymineless death through TS inhibition. Sequential metabolite activation enhances tumor selectivity and synergistic kill.​

• Cyclophosphamide: Prodrug activated by hepatic CYP2B6/3A4/2C9 to 4-hydroxycyclophosphamide → phosphoramide mustard; alkylates DNA at N7-guanine/C6-adenine forming monoadducts → interstrand crosslinks, activating Fanconi anemia/ATR/CHK1 DNA damage response → G2/M arrest → caspase-mediated apoptosis​
• Doxorubicin: Intercalates GC-rich DNA sequences stabilizing topoisomerase IIα-DNA cleavage complexes, preventing religase activity → persistent DSBs; redox cycling generates superoxide/quinone semiquinone ROS damaging mtDNA/lipids; p53-independent apoptosis via JNK pathway​
• Fluorouracil: Sequential activation → FdUMP binds thymidylate synthase + 5,10-methyleneTHF ternary complex → dTTP depletion → “thymineless death”; FUTP misincorporates into rRNA/mRNA disrupting maturation/translation; FdUTP DNA incorporation → MMR futile excision → DSBs → apoptosis​
• Combination synergy: S-phase fluorouracil sensitizes to doxorubicin strand breaks; cyclophosphamide metabolites exacerbate nucleotide imbalance; non-overlapping resistance mechanisms maximize cell kill​

FDA Approved Clinical Indications

CAF primarily targets breast cancer in adjuvant and neoadjuvant settings for patients with axillary node involvement, though contemporary guidelines favor anthracycline-taxane sequences due to superior efficacy-toxicity ratios. Individual agents retain broader oncology applications.​

• Oncological uses:
  • Adjuvant chemotherapy for operable node-positive (≥1-3 nodes) early-stage breast cancer (historical standard; 4-6 cycles every 21-28 days)​
  • Neoadjuvant therapy for locally advanced breast cancer (Stage IIB-IIIC; tumor downsizing prior to surgery)​
  • Palliative treatment of metastatic breast cancer (anthracycline-naïve patients; response rates 50-70%)​
• Non-oncological uses: None for CAF combination; cyclophosphamide used in autoimmune diseases​

Dosage and Administration Protocols

Standard CAF delivers equimolar Day 1 IV bolus dosing every 21-28 days for 4-6 cycles, with mandatory cardiac function monitoring due to doxorubicin cumulative dose limits (450-550 mg/m² lifetime). Aggressive antiemetic prophylaxis and growth factor support optimize delivery.​

Clinical Efficacy and Research Results

Seminal NSABP B-11/B-15 trials (1976-1980s enrollment, 20+ year follow-up through 2020s) established CAF superiority over CMF; however, meta-analyses confirm inferiority to modern AC→paclitaxel (HR 0.83 DFS benefit). Utility persists in resource-limited settings.​

• 10-year disease-free survival: 60-67% node-positive patients (NSABP B-15); 15-year OS 68% vs 62% no chemo​
• Pathologic complete response (pCR) neoadjuvant: 12-18% in operable breast cancer​
• Metastatic first-line ORR: 55-70%; median PFS 7-9 months; OS 18-24 months​
• EBCTCG meta-analysis: Anthracycline regimens (CAF-like) reduce recurrence 20%, mortality 16% vs CMF​

Safety Profile and Side Effects

Black Box Warning (Doxorubicin): Severe irreversible myocardial injury may occur, including therapy-related congestive heart failure and cardiomyopathy; incidence increases with cumulative dose. Regular cardiac function monitoring mandatory.​

Common Side Effects (>10%)

• Nausea/vomiting (80-90%; NK1 antagonist + 5HT3 + dexamethasone + olanzapine day 1-4)​
• Alopecia (95%; complete scalp/body hair loss by cycle 2, regrowth 3-6 months post)​
• Neutropenia (70-80% Grade 3/4 nadir day 10-14; primary G-CSF pegfilgrastim 6 mg day 2)​
• Mucositis/stomatitis (40-50%; oral cryotherapy 30 min pre/post 5-FU, benzydamine rinse)​
• Fatigue (50-60%; moderate aerobic exercise, protein 1.2 g/kg/day)​

Serious Adverse Events

• Cardiomyopathy/CHF (1-5% at 550 mg/m² cumulative; baseline/repeat MUGA q2 cycles, hold if LVEF <50% or 10% decline)​
• Febrile neutropenia (15-25%; hospitalize ceftriaxone + vancomycin, G-CSF until ANC >1k)​
• Palmar-plantar erythrodysesthesia (5-FU 20%; 10% urea cream BID, celecoxib 200 mg BID prophylaxis)​
• Therapy-related myeloid neoplasms (cyclophosphamide <1% at 5 years; annual CBC surveillance)​

Patient Management and Practical Recommendations

Cumulative doxorubicin cardiac risk mandates serial LVEF monitoring; fertility preservation counseling is critical given high gonadotoxicity, particularly in women <40 years.​

Pre-treatment Tests

• Baseline multigated acquisition (MUGA) scan or echocardiogram (LVEF ≥50-55%)​
• Comprehensive bloodwork (CBC/differential, CMP, magnesium, phosphorus, pregnancy test)​
• Fertility preservation consultation (oocyte/embryo cryopreservation, sperm banking)​

Precautions During Treatment

• Strict cumulative doxorubicin documentation (≤450 mg/m² preferred, 550 mg/m² absolute max)​
• Antiemetic bundle + primary G-CSF prophylaxis (febrile neutropenia risk >20%)​
• Weekly CBC nadir monitoring cycles 1-2​

Do’s and Don’ts

• Do attend mandatory cardiac function testing every 2 cycles​
• Do use scalp cooling if available (reduces alopecia 50%)​
• Do maintain barrier contraception during/12 months post-treatment​
• Don’t exceed lifetime anthracycline limits​
• Don’t breastfeed during/10 days post-cycle​

Legal Disclaimer

This guide provides general information about the CAF chemotherapy regimen and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations based upon complete clinical evaluation. Treatment decisions should consider individual patient risk-benefit profiles, cardiac function, and contemporary guideline preferences, and this content does not endorse any specific therapy.